Loss of FAM60A attenuates cell proliferation in glioma via suppression of PI3K/Akt/mTOR signaling pathways

被引:9
作者
Liu, Xiaocen [1 ,2 ,4 ]
Zhang, Mengying [1 ,3 ,4 ]
Zhu, Xiaolong [1 ,3 ,4 ]
Wang, Yingying [2 ]
Lv, Kun [1 ,3 ,4 ]
Yang, Hui [1 ,3 ,4 ]
机构
[1] Wannan Med Coll, Key Lab Noncoding RNA Transformat Res Anhui Highe, Wuhu 241001, Peoples R China
[2] Yijishan Hosp Wannan Med Coll, Affiliated Hosp Wannan Med Coll 1, Dept Nucl Med, Wuhu 241001, Peoples R China
[3] Yijishan Hosp Wannan Med Coll, Affiliated Hosp Wannan Med Coll 1, Cent Lab, Wuhu 241001, Peoples R China
[4] Noncoding RNA Res Ctr Wannan Med Coll, Wuhu 241001, Peoples R China
来源
TRANSLATIONAL ONCOLOGY | 2021年 / 14卷 / 11期
基金
中国国家自然科学基金;
关键词
FAM60A; Cell proliferation; PI3K; Akt; mTOR; Glioma; Biomarker; CANCER;
D O I
10.1016/j.tranon.2021.101196
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Glioma is a common malignant tumor of the central nervous system with a high incidence and mortality. Family with sequence similarity 60 member A (FAM60A) is a new subunit of the Sin3 deacetylase complex. The clinical significance and biologic role of FAM60A in glioma remain unclear. Methods: The expression of FAM60A in normal glial cells, glioma cells, and five-paired gliomas, and adjacent noncancerous tissues was quantified using real-time polymerase chain reaction (PCR) and western blotting. FAM60A protein expression in 179 archived, paraffin-embedded glioma samples was analyzed using immunohistochemistry. The roles of FAM60A in glioma cell proliferation and tumorigenicity were explored in vitro and in vivo. The underlying molecular mechanisms were elucidated using Western blot assay. Serum exosomal FAM60A levels of glioma patients were detected using electron microscopy, western blot, and real-time PCR. Results: FAM60A expression was significantly up-regulated in glioma tissues and cell lines and positively associated with a worse outcome in glioma. Knockdown of FAM60A could inhibit glioma cell proliferation and tumorigenicity in vitro and in vivo. Besides, FAM60A expression was detectable in extracted serum exosomes with a higher expression in the glioma cancer group than in the normal group. Conclusions: Loss of FAM60A attenuates cell proliferation in glioma by suppressing PI3K/Akt/mTOR signaling pathways. Therefore, FAM60A may act as a prognostic biomarker and therapeutic target for glioma.
引用
收藏
页数:8
相关论文
共 27 条
  • [1] Exosomes in bodily fluids are a highly stable resource of disease biomarkers
    Boukouris, Stephanie
    Mathivanan, Suresh
    [J]. PROTEOMICS CLINICAL APPLICATIONS, 2015, 9 (3-4) : 358 - 367
  • [2] The Somatic Genomic Landscape of Glioblastoma
    Brennan, Cameron W.
    Verhaak, Roel G. W.
    McKenna, Aaron
    Campos, Benito
    Noushmehr, Houtan
    Salama, Sofie R.
    Zheng, Siyuan
    Chakravarty, Debyani
    Sanborn, J. Zachary
    Berman, Samuel H.
    Beroukhim, Rameen
    Bernard, Brady
    Wu, Chang-Jiun
    Genovese, Giannicola
    Shmulevich, Ilya
    Barnholtz-Sloan, Jill
    Zou, Lihua
    Vegesna, Rahulsimham
    Shukla, Sachet A.
    Ciriello, Giovanni
    Yung, W. K.
    Zhang, Wei
    Sougnez, Carrie
    Mikkelsen, Tom
    Aldape, Kenneth
    Bigner, Darell D.
    Van Meir, Erwin G.
    Prados, Michael
    Sloan, Andrew
    Black, Keith L.
    Eschbacher, Jennifer
    Finocchiaro, Gaetano
    Friedman, William
    Andrews, David W.
    Guha, Abhijit
    Iacocca, Mary
    O'Neill, Brian P.
    Foltz, Greg
    Myers, Jerome
    Weisenberger, Daniel J.
    Penny, Robert
    Kucherlapati, Raju
    Perou, Charles M.
    Hayes, D. Neil
    Gibbs, Richard
    Marra, Marco
    Mills, Gordon B.
    Lander, Eric
    Spellman, Paul
    Wilson, Richard
    [J]. CELL, 2013, 155 (02) : 462 - 477
  • [3] Progress Toward Long-Term Survivors of Glioblastoma
    Cantrell, J. Nathan
    Waddle, Mark R.
    Rotman, Maarten
    Peterson, Jennifer L.
    Ruiz-Garcia, Henry
    Heckman, Michael G.
    Quinones-Hinojosa, Alfredo
    Rosenfeld, Steven S.
    Brown, Paul D.
    Trifiletti, Daniel M.
    [J]. MAYO CLINIC PROCEEDINGS, 2019, 94 (07) : 1278 - 1286
  • [4] Glioma Subclassifications and Their Clinical Significance
    Chen, Ricky
    Smith-Cohn, Matthew
    Cohen, Adam L.
    Colman, Howard
    [J]. NEUROTHERAPEUTICS, 2017, 14 (02) : 284 - 297
  • [5] miRNAs, cancer, and stem cell division
    Croce, CM
    Calin, GA
    [J]. CELL, 2005, 122 (01) : 6 - 7
  • [6] Integrative analysis of copy number and transcriptional expression profiles in esophageal cancer to identify a novel driver gene for therapy
    Dong, Gaochao
    Mao, Qixing
    Yu, Decai
    Zhang, Yi
    Qiu, Mantang
    Dong, Gaoyue
    Chen, Qiang
    Xia, Wenjie
    Wang, Jie
    Xu, Lin
    Jiang, Feng
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [7] The PI3K Pathway in Human Disease
    Fruman, David A.
    Chiu, Honyin
    Hopkins, Benjamin D.
    Bagrodia, Shubha
    Cantley, Lewis C.
    Abraham, Robert T.
    [J]. CELL, 2017, 170 (04) : 605 - 635
  • [8] Insular glioma surgery: an evolution of thought and practice
    Hervey-Jumper, Shawn L.
    Berger, Mitchel S.
    [J]. JOURNAL OF NEUROSURGERY, 2019, 130 (01) : 9 - 16
  • [9] Jhanwar-Uniyal Meena, 2019, Advances in Biological Regulation, V72, P51, DOI 10.1016/j.jbior.2019.03.003
  • [10] A novel radiological classification system for cerebral gliomas: The Brain-Grid
    Latini, Francesco
    Fahlstrom, Markus
    Berntsson, Shala G.
    Larsson, Elna-Marie
    Smits, Anja
    Ryttlefors, Mats
    [J]. PLOS ONE, 2019, 14 (01):